



Cycloartane triterpenoids from the aerial parts of *Cimicifuga foetida* Linnaeus

Yin Nian^{a,b}, Xian-Min Zhang^a, Yan Li^a, Yuan-Yuan Wang^a, Jian-Chao Chen^a, Lu Lu^{a,b}, Lin Zhou^a, Ming-Hua Qiu^{b,*}

^aState Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650204, PR China

^bGraduate School of the Chinese Academy of Sciences, Beijing 100039, PR China

ARTICLE INFO

Article history:

Received 4 May 2010

Received in revised form 25 November 2010

Available online 10 May 2011

Keywords:

Cimicifuga foetida

Ranunculaceae

Cycloartane triterpenoids

Cytotoxicity

Structure–activity relationships

ABSTRACT

Cycloartane triterpenoids, 2',24-O-diacetylisdahurinol-3-O- α -L-arabinopyranoside, 24-O-acetylisdahurinol-3-O- α -L-arabinopyranoside, 12 β -hydroxy-25-anhydrocimigenol, cimigenol-12-one, 12 β -hydroxy-15-deoxycimigenol, 2'-O-acetyl-24-*epi*-cimigenol-3-O- α -L-arabinopyranoside, 2'-O-acetylcimigenol-3-O- β -D-xylopyranoside, 25-anhydrocimigenol-3-O- α -L-arabinopyranoside, 2',23-O-diacetylshengmanol-3-O- α -L-arabinopyranoside, and 2',24-O-diacetyl-25-anhydroshengmanol-3-O- α -L-arabinopyranoside, together with eight known compounds, were isolated from aerial parts of *Cimicifuga foetida*. Their structures were determined by application of spectroscopic analyses and chemical methods. Biological evaluation of the compounds against human HL-60, SMMC-7721, A549, SK-BR-3, and PANC-1 cell lines indicated that three of these compounds exhibited broad-spectrum and moderate cytotoxic activities, with IC₅₀ values ranging from 6.20 to 22.74 μ M. By comparing previous cytotoxic testing data and bioassay results from this study, preliminary structure–activity relationships of compounds with a cimigenol-skeleton can be proposed.

© 2011 Elsevier Ltd. All rights reserved.

1. Introduction


The genus *Cimicifuga* (now *Actaea* in the western world) consists of 28 species, whose roots have been used in traditional medicine worldwide (Compton et al., 1998a,b; Liske and Wustenberg, 1998). *C. foetida*, one of the most common Asiatic species, has been employed as cooling and detoxification agents by the Chinese since ancient times (Pharmacopoeia Commission of the People's Republic of China, 2005). Intrigued by the theory of Chinese traditional medicine, in which a tumor is defined as a kind of toxin, we have been studying the potential antitumor constituents of *C. foetida* and reported a series of cycloartane triterpenoids from the roots, which exhibited cytotoxicities against various tumor cell lines (Sun et al., 2007; Nian et al., 2010; Lu et al., 2010). Triterpene glycosides, such as cimicifoetisides A and B, showed significant activities against rat Ehrlich ascites carcinoma (EAC), with IC₅₀ values of 0.52 and 0.19 μ M, respectively. In addition, analogs like 4'-O-(*E*)-2-butenoyl-25-O-acetylcimigenol-3-O- β -D-xylopyranoside, 3',25-O-diacetyl-cimigenol-3-O- β -D-xylopyranoside and 3'-O-acetyl-23-*epi*-26-deoxyactein exhibited potent and selective cytotoxic-

ity against human HepG2 cells, having IC₅₀ values of 1.29, 0.71 and 1.41 μ M, respectively.


In the past, the aerial parts of *C. foetida* were discarded as a waste by-product in China. Recently, other research groups have paid attention to its chemical properties and a series of 9,19-cycloartane triterpene glycosides have been obtained (Pan et al., 2002, 2003, 2004, 2007, 2009; Tian et al., 2006). In addition, one group reported that the ethyl acetate fraction of an 80% ethanol extract of the tissue and several isolated cycloartane triterpenoids displayed growth inhibitory activities against human hepatoma cell lines (Tian et al., 2006, 2007). In an attempt to fully explore the chemical constituents and their cytotoxicities of this medicinal plant, we undertook phytochemical and pharmacological investigations on the aerial parts of *C. foetida*. Ten 9,19-cycloartane triterpenes (**1–10**), together with eight known compounds (Scheme 1), 12 β -hydrocimigenol-3-one (**11**) (Nian et al., 2009), 4',23-O-diacetylshengmanol-3-O- α -L-arabinopyranoside (**12**) (Chen et al., 2002), 23-O-acetylshengmanol-3-O- α -L-arabinopyranoside (**13**) (Kusano et al., 1999), 12 β -O-acetylcimiracemonol (**14**) (Zhou et al., 2004), 25-O-acetylcimigenol-3-O- α -L-arabinopyranoside (**15**) (Ye et al., 1999), isodahurinol (**16**) (Kusano et al., 1976), 12 β -hydrocimigenol-3-O- β -D-xylopyranoside (**17**) (Kusano et al., 1995), and 12 β -hydrocimigenol (**18**) (Kusano et al., 1995), were isolated and identified. The isolated compounds were tested for their cytotoxicities against human HL-60, SMMC-7721, A549, SK-BR-3, and PANC-1 cell lines, using the MTT method.

* Corresponding author. Tel.: +86 871 5223257; fax: +86 871 5223255.


E-mail address: mhchiu@mail.kib.ac.cn (M.-H. Qiu).




- 1 $R_1 = -O-2'-O\text{-acetyl-}\alpha\text{-L-arabinose}$, $R_2 = OAc$
 2 $R_1 = -O-\alpha\text{-L-arabinose}$, $R_2 = OAc$
 16 $R_1 = OH$, $R_2 = OH$




- 3 $R_1 = OH$, $R_2 = OH$, $R_3 = OH$
 8 $R_1 = -O-\alpha\text{-L-arabinose}$, $R_2 = H$, $R_3 = OH$




- 4 $R_1 = OH$, $R_2 = =O$, $R_3 = OH$, $R_4 = OH$
 5 $R_1 = OH$, $R_2 = OH$, $R_3 = H$, $R_4 = OH$
 6 $R_1 = -O-2'-O\text{-acetyl-}\alpha\text{-L-arabinose}$, $R_2 = H$, $R_3 = OH$, $R_4 = OH$; 24R
 7 $R_1 = -O-2'-O\text{-acetyl-}\beta\text{-D-xylose}$, $R_2 = H$, $R_3 = OH$, $R_4 = OH$
 11 $R_1 = =O$, $R_2 = OH$, $R_3 = OH$, $R_4 = OH$
 15 $R_1 = -O-\alpha\text{-L-arabinose}$, $R_2 = H$, $R_3 = OH$, $R_4 = OAc$
 17 $R_1 = -O-\beta\text{-D-xylose}$, $R_2 = OH$, $R_3 = OH$, $R_4 = OH$
 18 $R_1 = OH$, $R_2 = OH$, $R_3 = OH$, $R_4 = OH$



- 9 $R_1 = -O-2'-O\text{-acetyl-}\alpha\text{-L-arabinose}$
 12 $R_1 = -O-4'-O\text{-acetyl-}\alpha\text{-L-arabinose}$
 13 $R_1 = -O-\alpha\text{-L-arabinose}$



10



14

Scheme 1. Structures of compounds isolated from the aerial parts of *C. foetida*.

2. Results and discussion

2.1. Characterization of the compounds

Compound **1**, isolated as a white powder, gave a pseudo-molecular ion at m/z 727 $[M+Na]^+$ in the positive ion ESIMS. The IR spectrum showed absorptions for hydroxyl (3410 cm^{-1}) and carbonyl (1741 cm^{-1}) groups. Analysis of the ^{13}C NMR and HR-ESIMS (m/z 727.4048 $[M+Na]^+$) determined its molecular formula as $\text{C}_{39}\text{H}_{60}\text{O}_{11}$. The assignment of ^1H and ^{13}C NMR spectroscopic data of **1** (Tables 1 and 2) was based on analysis of HSQC, HMBC (Fig. 1), and $^1\text{H}-^1\text{H}$ COSY data. The ^1H NMR spectrum (Table 1)

showed signals due to the characteristic cyclopropane methylene at δ_{H} 0.18 and 0.41 (1H each, $d, J = 4.0\text{ Hz}$), six *tert*-methyl groups at δ_{H} 0.91, 0.97, 1.07, 1.15, 1.60 ($2\times$), two acetoxymethyl groups at δ_{H} 2.11 and 2.15, a *sec*-methyl group at δ_{H} 0.89 ($d, J = 6.0\text{ Hz}$), and an anomeric proton at δ_{H} 4.72 ($d, J = 7.6\text{ Hz}$). The ^{13}C NMR and DEPT spectrum of **1** (Table 2) exhibited data consistent with a cyclopropane methylene at δ_{C} 31.0 (C-19), five oxygenated carbons at δ_{C} 88.5 (C-3), 84.2 (C-16), 79.9 (C-24), 79.0 (C-23), and 72.0 (C-25), a carbonyl carbon at δ_{C} 214.0, and a pentose moiety at δ_{C} 104.6 (C-1'), 74.4 (C-2'), 72.5 (C-3'), 69.8 (C-4'), and 67.3 (C-5'). This spectrum also indicated two acetoxy carbonyl groups at δ_{C} 171.1 and 170.1. This evidence suggested that **1** was a highly oxygenated

Table 1
¹H NMR spectroscopic data of compounds **1–10** in pyridine-*d*₅.

Proton	1 δ_{H} multi. (<i>J</i> in Hz)	2 δ_{H} multi. (<i>J</i> in Hz)	3 δ_{H} multi. (<i>J</i> in Hz)	4 δ_{H} multi. (<i>J</i> in Hz)	5 δ_{H} multi. (<i>J</i> in Hz)	6 δ_{H} multi. (<i>J</i> in Hz)	7 δ_{H} multi. (<i>J</i> in Hz)	8 δ_{H} multi. (<i>J</i> in Hz)	9 δ_{H} multi. (<i>J</i> in Hz)	10 δ_{H} multi. (<i>J</i> in Hz)
1	1.50 m	1.52 m	1.58 m	1.53 m	1.57 m	1.50 m	1.53 m	1.57 m	1.54 m	1.53 m
	1.12 m	1.14 m	1.24 m	1.05 m	1.24 m	1.16 m	1.16 m	1.20 m	1.19 m	1.18 m
2	2.23 m	2.36 <i>dd</i> (12.8, 3.2)	1.95 m	1.94 <i>dd</i> (13.2, 4.0)	1.95 <i>brd</i> (10.0)	2.26 <i>brd</i> (10.5)	2.24 m	2.38 m	2.28 m	2.25 m
	1.83 m	1.91 m	1.85 m	1.87 <i>dd</i> (12.2, 3.6)	1.84 m	1.87 <i>dd</i> (12.0, 2.5)	1.87 <i>dd</i> (12.5, 3.5)	1.95 <i>dd</i> (12.5, 3.5)	1.89 m	1.88 m
3	3.35 <i>dd</i> (11.8, 4.4)	3.48 <i>dd</i> (11.6, 4.0)	3.53 <i>dd</i> (11.3, 4.0)	3.52 <i>dd</i> (11.4, 4.0)	3.52 <i>dd</i> (11.8, 4.0)	3.36 <i>dd</i> (11.3, 4.0)	3.37 <i>dd</i> (12.0, 4.5)	3.50 <i>dd</i> (11.8, 4.0)	3.37 <i>dd</i> (11.5, 4.0)	3.36 <i>dd</i> (11.6, 4.4)
4										
5	1.24 m	1.27 m	1.82 <i>brd</i> (10.5)	1.90 m	1.28 m	1.28 m	1.28 m	1.33 <i>dd</i> (12.5, 4.0)	1.34 m	1.33 <i>dd</i> (12.4, 4.4)
6	1.46 <i>brd</i> (12.0)	1.46 <i>brd</i> (12.8)	1.61 <i>brd</i> (12.0)	1.55 m	1.59 m	1.55 m	1.53 m	1.53 m	1.55 m	1.55 m
	0.57 m	0.57 m	0.83 m	0.80 m	0.84 m	0.72 m	0.70 m	0.70 m	0.73 m	0.75 m
7	1.90 m	1.93 m	2.25 m	2.19 m	1.63 <i>brd</i> (4.5)	2.09 m	2.11 m	2.06 m	2.11 m	2.06 m
	1.28 m	1.26 m	1.20 m	1.08 m	1.11 m	1.12 m	1.12 m	1.18 m	1.12 m	1.05 m
8	1.66 m	1.67 m	1.31 <i>dd</i> (12.5, 4.5)	1.23 m	1.66 <i>brd</i> (5.0)	1.67 m	1.66 m	1.68 <i>dd</i> (12.5, 4.0)	1.85 m	1.79 m
9										
10										
11	2.23 m	2.23 m	2.84 <i>dd</i> (15.5, 9.0)	2.85 <i>d</i> (20.0)	2.71 <i>dd</i> (15.8, 8.5)	2.01 m	2.04 m	2.14 m	2.08 m	2.16 m
	0.99 m	1.01 m	1.48 m	2.09 <i>d</i> (20.0)	1.50 m	1.03 m	1.03 m	1.05 m	1.08 m	1.23 m
12	1.56 m	1.57 m	4.18 m		4.22 <i>brd</i> (9.0)	1.64 m	1.62 m	1.64 m	1.78 m	1.77 <i>dd</i> (12.2, 4.4)
	1.36 m	1.34 m				1.57 m	1.52 m	1.53 m	1.78 m	1.58 m
13										
14										
15			4.49 <i>brs</i>	4.48 <i>brs</i>	2.26 <i>d</i> (14.0)	4.24 <i>brs</i>	4.25 <i>brs</i>	4.30 <i>brs</i>	4.38 <i>brs</i>	4.14 <i>brs</i>
					2.09 <i>d</i> (14.0)					
16	3.79 <i>d</i> (11.6)	3.79 <i>dd</i> (3.6, 11.4)								
17	1.56 m	1.57 m	1.80 m	2.30 <i>brd</i> (11.2)	1.95 <i>brd</i> (10.0)	1.76 <i>brd</i> (11.5)	1.75 m	1.44 <i>d</i> (11.0)	2.34 <i>d</i> (6.5)	1.88 m
18	1.15 s	1.14 s	1.44 s	1.33 s	1.42 s	1.17 s	1.13 s	1.13 s	1.38 s	1.27 s
19	0.41 <i>d</i> (4.0)	0.45 <i>d</i> (4.0)	0.65 <i>d</i> (4.0)	0.69 <i>d</i> (4.0)	0.65 <i>d</i> (4.0)	0.47 <i>brs</i>	0.45 <i>d</i> (4.0)	0.51 <i>d</i> (4.0)	0.50 <i>d</i> (4.0)	0.53 <i>d</i> (4.0)
	0.18 <i>d</i> (4.0)	0.22 <i>d</i> (4.0)	0.41 <i>d</i> (4.0)	0.39 <i>d</i> (4.0)	0.35 <i>d</i> (4.0)	0.23 <i>d</i> (3.0)	0.22 <i>d</i> (4.0)	0.26 <i>d</i> (4.0)	0.24 <i>d</i> (4.0)	0.26 <i>d</i> (4.0)
20	1.79 m	1.79 m	1.80 m	1.62 m	1.86 m	1.67 m	1.66 m	1.61 <i>brt</i> (6.0)	2.11 m	1.79 m
21	0.89 <i>d</i> (6.0)	0.89 <i>d</i> (6.0)	1.39 <i>d</i> (6.0)	1.11 <i>d</i> (6.4)	1.38 <i>d</i> (6.5)	0.94 <i>d</i> (6.0)	0.82 <i>d</i> (6.5)	0.83 <i>d</i> (6.5)	1.25 <i>d</i> (6.5)	1.01 <i>brd</i> (4.4)
22	1.70 m	1.71 m	2.33 m	2.35 <i>dd</i> (6.6, 2.8)	2.38 m	2.66 <i>t</i> (12.0)	2.27 m	2.19 m	2.67 <i>t</i> (12.5)	1.82 m
	1.46 <i>brd</i> (12.0)	1.46 <i>brd</i> (12.8)	1.06 m		1.12 m	1.92 m	1.03 m	0.97 m	1.75 m	1.72 m
23	4.23 m	4.23 <i>t</i> (11.6)	4.33 <i>d</i> (9.0)	4.79 <i>d</i> (9.2)	4.80 <i>d</i> (8.5)	4.59 <i>brd</i> (10.0)	4.64 <i>d</i> (9.0)	4.28 <i>brd</i> (7.0)	5.40 <i>brt</i> (8.5)	4.11 m
24	5.31 <i>d</i> (2.0)	5.30 <i>d</i> (1.6)	4.22 <i>brs</i>	3.78 <i>brs</i>	3.77 <i>brs</i>	3.68 <i>d</i> (4.0)	4.15 s	4.15 <i>brs</i>	3.02 <i>d</i> (8.5)	6.02 <i>d</i> (9.2)
25										
26	1.60 s	1.60 s	5.35 <i>brs</i>	1.47 s	1.53 s	1.42 s	1.28 s	5.33 s	1.23 s	5.19 <i>brs</i>
			4.89 <i>brs</i>					4.87 s		5.00 <i>brs</i>
27	1.60 s	1.60 s	1.86 s	1.47 s	1.47 s	1.26 s	1.27 s	1.82 s	1.37 s	1.82 s
28	0.97 s	0.98 s	1.22 s	1.08 s	1.24 s	1.06 s	1.16 s	1.16 s	1.19 s	1.24 s
29	1.07 s	1.27 s	1.20 s	1.18 s	1.22 s	1.07 s	0.96 s	1.29 s	1.08 s	1.09 s
30	0.91 s	0.98 s	1.06 s	1.08 s	1.07 s	0.97 s	1.07 s	1.03 s	0.97 s	0.95 s
<i>Ara</i> (at C-3)										
1□	4.72 <i>d</i> (7.6)	4.78 <i>d</i> (7.2)				4.72 <i>d</i> (7.5)		4.80 <i>d</i> (7.0)	4.75 <i>d</i> (7.5)	4.74 <i>d</i> (7.2)
2□	5.91 <i>t</i> (8.8)	4.45 <i>t</i> (8.4)				5.91 <i>t</i> (8.5)		4.17 m	5.93 <i>t</i> (8.5)	5.84 <i>t</i> (8.4)
3□	4.18 <i>dd</i> (9.4, 3.2)	4.16 <i>dd</i> (8.8, 2.8)				4.17 <i>brd</i> (8.5)		4.46 <i>t</i> (8.0)	4.19 <i>dd</i> (9.5, 3.2)	4.16 <i>dd</i> (10.2, 4.0)
4□	4.27 m	4.31 m				4.27 m		4.30 <i>brs</i>	4.29 m	4.28 m
5□	4.27 m	4.28 <i>t</i> (11.6)				4.27 m		4.28 <i>brd</i> (7.0)	4.29 m	4.28 m
	3.75 <i>t</i> (11.2)	3.79 <i>dd</i> (11.4, 3.6)				3.75 m		3.79 <i>d</i> (11.0)	3.78 <i>brd</i> (11.0)	3.77 <i>d</i> (11.2)

(continued on next page)

Table 1 (continued)

Proton	1	2	3	4	5	6	7	8	9	10
	δ_{H} multi. (J in Hz)	δ_{H} multi. (J in Hz)	δ_{H} multi. (J in Hz)	δ_{H} multi. (J in Hz)	δ_{H} multi. (J in Hz)	δ_{H} multi. (J in Hz)	δ_{H} multi. (J in Hz)	δ_{H} multi. (J in Hz)	δ_{H} multi. (J in Hz)	δ_{H} multi. (J in Hz)
Xyl (at C-3)										
1□							4.81 d (8.0)			
2□							5.56 t (8.0)			
3□							4.19 m			
4□							4.13 m			
5□							4.30 dd (11.3, 5.0)			
							3.67 t (10.0)			
C ₂₃ acetyl	2.15 s								2.04 s	1.93 s
C ₂₄ acetyl	2.11 s	2.15 s				2.11 s			2.12 s	2.11 s
C ₂ acetyl							2.14 s			

9,19-cycloartane triterpene monoglycoside with two acetoxy groups. The NMR spectroscopic data (Tables 1 and 2) of **1** resembled those of 24-acetylisodahurinol-3-O- β -D-xylopyranoside (Shao et al., 2000) except for the presence of a sugar unit. In the ^1H NMR spectrum, a downfield resonance was observed at δ_{H} 5.91 ($t, J = 8.8$ Hz), which showed correlations with the methine resonance at δ_{H} 4.18 (H-3') and with the anomeric proton at δ_{H} 4.72 in the ^1H - ^1H COSY spectrum. In addition, the HMBC (Fig. 1) correlation between the O-acetyl group (δ_{C} 170.1) and the proton (δ_{H} 5.91, $t, J = 8.8$ Hz) resonances indicated the O-acetyl group was attached at C-2'. The sugar obtained after acid hydrolysis was identified as L-arabinose by comparing its TLC and specific rotation with a standard. The HMBC correlation between H-1' at δ_{H} 4.72 ($d, J = 7.6$ Hz) and the methine signal at δ_{C} 88.5 (C-3) suggested that the sugar moiety was attached at C-3. In the ROESY spectrum (Fig. 2), H-3 showed a correlation with H-5 (biogenetically α -oriented), while H-16 showed a correlation with Me-28 (biogenetically α -oriented). Based on these observations, H-3 and H-16 were assigned in an α -orientation. The configuration of C-24 was deduced as S by comparison of the coupling constants of H-24 (2.4 Hz) with those of dahurinyl diacetate (9 Hz) and isodahurinyl diacetate (2 Hz) (Shao et al., 2000). Accordingly, compound **1** was characterized as 2',24-O-diacetylisodahurinol-3-O- α -L-arabinopyranoside.


Compound **2** was isolated as a white powder. The HR-ESIMS of **2** exhibited a sodiated molecular ion at m/z 685.3939 $[\text{M}+\text{Na}]^+$ for the molecular formula of $\text{C}_{37}\text{H}_{58}\text{O}_{10}$. In the ^1H NMR spectrum, compound **2** showed signals for a cyclopropane methylene at δ_{H} 0.22 and 0.45 (1H each, $d, J = 4.0$ Hz), six *tert*-methyl groups at δ_{H} 0.98 ($2\times$), 1.14, 1.27, 1.60 ($2\times$), a *sec*-methyl group at δ_{H} 0.89 ($d, J = 6.0$ Hz), and an anomeric proton resonance at δ_{H} 4.78 ($d, J = 7.2$ Hz), suggesting that **2** was a 9,19-cycloartane triterpene glycoside. In the ^{13}C NMR spectrum (Table 2), compound **2** had resonances corresponding to an arabinose moiety at δ_{C} 107.6 (d), 73.0 (d), 74.7 (d), 69.6 (d), and 66.9 (t) (Shao et al., 2000). The remaining 30 carbon signals were identical with the aglycone resonances of **1**. Therefore, **2** was elucidated as 24-O-acetylisodahurinol-3-O- α -L-arabinopyranoside.

Compound **3** was isolated as a white powder. In its HR-ESIMS, it showed a quasi-molecular ion at m/z 509.3256 $[\text{M}+\text{Na}]^+$ for a molecular formula of $\text{C}_{30}\text{H}_{46}\text{O}_5$. Its IR spectrum exhibited absorptions at 3423 and 1648 cm^{-1} , owing to hydroxyl groups and double bond stretches, respectively. The ^1H NMR spectrum (Table 1) displayed cyclopropane methylene signals at δ_{H} 0.41 and 0.65 (1H each, $d, J = 4.0$ Hz), six methyl groups at δ_{H} 1.06, 1.20, 1.22, 1.44, 1.86 and 1.39 ($d, J = 6.0$ Hz), an olefinic methylene at δ_{H} 4.89 and 5.35 (1H each, *brs*), respectively, suggesting **3** to be a 9,19-cyclolanostane aglycone with an olefinic methylene. The NMR spectroscopic data of **3** closely resembled those of 12 β -hydroxycimigenol (Kusano et al., 1995), except for the presence of two downfield signals at δ_{C} 113.1 and 146.0, and the absence of a quaternary carbon and a methyl resonance due to C-25 and C-26, respectively. On the basis of these observations, it was reasonable to deduce that **3** was a 25-dehydrated derivative of 12 β -hydroxycimigenol, this also being supported by the HMBC correlations of H-27 at δ_{H} 1.86 with C-25 (δ_{C} 146.0), C-26 (δ_{C} 113.1), and C-24 (δ_{C} 86.7). Significant ROESY correlations of H-3 with H-5 (biogenetically α -oriented) suggested a β -orientation of the substituent at C-3, whereas the associations of H-15 with H-8 and Me-18 (biogenetically β -oriented), indicated an α -orientation of the hydroxy group at C-15. The configurations of C-23 and C-24 are proposed as R and S, respectively, by comparing the coupling constants of H-23 and H-24 of **3** with those of known 9,19-cyclolanostane triterpene glycosides (Chen et al., 2002). Therefore, **3** was elucidated as 12 β -hydroxy-25-anhydrocimigenol.

Compound **4** was isolated as a white powder. Its molecular formula $\text{C}_{30}\text{H}_{46}\text{O}_6$ was deduced from the ^{13}C NMR data and the posi-

Table 2
¹³C NMR spectroscopic data of compounds **1–10** in pyridine-*d*₅.

Cpd/C	1	2	3	4	5	6	7	8	9	10
1	32.3 t	32.5 t	32.8 t	32.9 t	32.3 t	32.3 t	32.3 t	32.5 t	32.1 t	32.3 t
2	30.0 t	30.1 t	31.3 t	31.1 t	31.2 t	30.0 t	30.0 t	30.1 t	30.0 t	29.8 t
3	88.5 d	88.4 d	78.0 d	77.6 d	77.9 d	88.7 d	88.7 d	88.6 d	88.6 d	88.7 d
4	41.0 s	41.3 s	41.1 s	41.0 s	41.0 s	41.0 s	41.9 s	41.7 s	41.5 s	41.0 s
5	47.2 d	47.4 d	47.5 d	47.9 d	47.1 d	47.5 d	47.5 d	47.7 d	47.3 d	47.5 d
6	20.8 t	20.8 t	21.2 t	20.7 t	21.0 t	21.1 t	21.1 t	21.1 t	21.0 t	21.0 t
7	26.0 t	26.1 t	26.3 t	26.5 t	26.1 t	26.5 t	26.5 t	26.7 t	26.7 t	26.5 t
8	43.6 d	43.6 d	47.3 d	46.7 d	45.9 d	48.7 d	48.7 d	48.7 d	48.3 d	49.0 d
9	20.0 s	20.0 s	20.7 s	20.0 s	20.4 s	20.1 s	20.1 s	20.1 s	20.1 s	20.4 s
10	27.0 s	27.0 s	26.9 s	27.9 s	27.0 s	26.6 s	26.6 s	26.7 s	26.7 s	26.7 s
11	25.9 t	25.9 t	41.1 t	45.5 t	41.0 t	26.3 t	26.4 t	26.4 t	25.9 t	26.5 t
12	31.3 t	31.3 t	72.9 d	211.0 s	72.4 d	34.0 t	34.1 t	34.1 t	33.0 t	34.1 t
13	40.0 s	40.0 s	48.3 s	56.9 s	45.7 s	41.8 s	41.9 s	41.4 s	41.0 s	42.1 s
14	55.0 s	55.0 s	47.8 s	48.3 s	52.2 s	47.4 s	47.3 s	47.3 s	46.0 s	46.7 s
15	214.0 s	214.0 s	80.1 d	79.1 d	46.9 t	80.8 d	80.2 d	80.4 d	83.0 d	82.4 d
16	84.2 d	84.2 d	112.7 s	111.7 s	115.0 s	112.2 s	112.0 s	112.3 s	220.0 s	103.4 s
17	52.3 d	52.3 d	60.2 d	51.0 d	61.4 d	60.8 d	59.5 d	59.9 d	60.0 d	60.6 d
18	20.3 q	20.3 q	12.1 q	12.2 q	11.8 q	19.6 q	19.5 q	19.5 q	19.8 q	20.4 q
19	31.0 t	31.1 t	31.0 t	31.0 t	30.1 t	30.9 t	30.8 t	30.9 t	30.4 t	30.7 t
20	33.2 d	33.2 d	23.9 d	24.5 d	23.7 d	23.5 d	24.0 d	23.9 d	28.0 d	27.3 d
21	20.0 q	20.0 q	20.9 q	20.1 q	21.8 q	19.6 q	19.6 q	19.5 q	20.3 q	21.2 q
22	38.7 t	38.7 t	38.8 t	38.4 t	38.6 t	29.6 t	38.2 t	38.1 t	37.0 t	32.3 t
23	79.0 d	79.0 d	74.9 d	71.6 d	72.0 d	73.7 d	71.6 d	75.0 d	72.1 d	74.7 d
24	79.9 d	79.8 d	86.7 d	90.3 d	90.3 d	84.1 d	90.0 d	86.7 d	65.2 d	82.7 d
25	72.0 s	72.0 s	146.0 s	71.0 s	71.0 s	68.6 s	71.4 s	145.9 s	58.5 s	142.2 s
26	26.8 q	26.8 q	113.1 t	25.3 q	27.9 q	30.7 q	25.4 q	113.0 t	24.7 q	115.8 t
27	28.3 q	28.3 q	18.2 q	27.2 q	24.8 q	25.9 q	23.0 q	18.2 q	19.3 q	18.3 q
28	17.6 q	17.6 q	12.0 q	12.7 q	19.5 q	11.7 q	11.8 q	11.9 q	12.0 q	11.8 q
29	25.4 q	25.7 q	26.1 q	26.1 q	26.2 q	25.5 q	25.4 q	25.8 q	25.4 q	25.5 q
30	15.2 q	15.4 q	14.8 q	14.8 q	14.8 q	15.3 q	15.3 q	15.4 q	15.2 q	15.2 q
Ara (at C-3)										
1□	104.6 d	107.6 d				104.6 d		107.4 d	104.5 d	104.3 d
2□	74.4 d	73.0 d				74.4 d		72.9 d	74.4 d	74.4 d
3□	72.5 d	74.7 d				72.5 d		74.7 d	72.5 d	72.5 d
4□	69.8 d	69.6 d				69.8 d		69.5 d	69.8 d	69.7 d
5□	67.3 t	66.9 t				67.3 t		66.7 t	67.3 t	67.3 t
Xyl (at C-3)										
1□							104.7 d			
2□							75.7 d			
3□							76.3 d			
4□							71.4 d			
5□							67.2 t			
C ₂₃ acetyl										
CO									170.6 s	
CH ₃									21.0 q	
C ₂₄ acetyl										
CO	171.1 s	171.1 s								170.3 s
CH ₃	21.0 q	21.0 q								21.2 q
C ₂ acetyl										
CO	170.1 s					170.0 s	170.0 s		170.0 s	170.0 s
CH ₃	21.4 q					21.3 q	21.3 q		21.3 q	21.4 q

**Fig. 1.** Major long-distance ¹H–¹³C correlations of **1**.

tive ion HR-ESIMS, which showed a molecular peak at m/z 525.3198 $[M+Na]^+$. In the IR spectrum, absorption bands at 3404 and 1709 cm^{-1} for hydroxyl and carbonyl groups were observed. The NMR spectroscopic data (Tables 1 and 2) of **4** resembled those of 12- β -hydroxycimigenol (Kusano et al., 1995) except for changes at C-11 (δ_C 45.5), C-12 (δ_C 211.0), and C-13 (δ_C 56.9) due to a hydroxyl group being replaced by a carbonyl group. The position of the carbonyl at C-12 was confirmed by correlations between H-11 (δ_H 2.09 and 2.85), Me-18 (δ_H 1.33) and C-12 (δ_C 211.0) in the HMBC spectrum. Thus compound **4** was characterized as cimigenol-12-one.

Compound **5** was isolated as a white powder. The negative ion ESIMS showed a pseudo-molecular ion at m/z 523 $[M+Cl]^-$, which in conjunction with ¹³C NMR spectroscopic data established the molecular formula as C₃₀H₄₈O₅. In the ¹H NMR spectrum, signals for the cyclopropane methylene at δ_H 0.35 and 0.65 (1H each, d , $J = 4.0$ Hz), six *tert*-methylene groups at δ_H 1.07, 1.22, 1.24, 1.42, 1.47, and 1.53, and a *sec*-methyl group at δ_H 1.38 (d , $J = 6.5$ Hz) were observed, suggesting **5** as a 9,19-cycloartane triterpene. The




Fig. 2. Key ROESY correlations of compound 1.

Table 3

Cytotoxicity of compounds isolated from the aerial parts of *Cimicifuga foetida* (IC₅₀ values; μM).

Compounds	HL-60	SMMC-7721	A-549	SK-BR-3	PANC-1
1	>40	>40	>40	>40	>40
2	>40	>40	>40	>40	>40
3	>40	>40	>40	>40	>40
4	>40	>40	>40	>40	>40
5	>40	17.65	>40	35.14	>40
6	>40	>40	>40	>40	>40
7	15.39	14.84	9.50	19.20	17.94
8	6.20	14.14	16.69	22.74	>40
9	35.24	>40	>40	>40	>40
10	31.68	>40	>40	>40	>40
11	>40	>40	>40	>40	>40
12	>40	>40	>40	>40	>40
13	>40	>40	>40	>40	>40
14	>40	>40	>40	>40	>40
15	13.37	14.80	15.65	17.35	17.72
16	>40	>40	>40	>40	>40
17	>40	>40	>40	>40	>40
18	>40	>40	>40	>40	>40
Cisplatin	0.75	14.13	26.54	22.51	19.47

¹³C NMR and DEPT spectroscopic data of **5** were identical with aglycone resonances of 12 β -hydroxy-15-deoxycimigenol-3-*O*- β -D-xylopyranoside (Yoshimitsu et al., 2006) except for the upfield shift of the C-3 by 7.6 ppm, which could be explained by the absence of a sugar unit at C-3. Therefore, **5** was elucidated as 12 β -hydroxy-15-deoxycimigenol.

Compound **6** was isolated as a white powder, which exhibited a pseudo-molecular ion at m/z 685 [M+Na]⁺ in the positive ion ESIMS. Analysis of its ¹³C NMR and HR-ESIMS m/z : 685.3915 (calc. 685.3927) helped confirm the molecular formula as C₃₇H₅₈O₁₀. The ¹³C and DEPT NMR spectrum of **6** (Table 2) showed signals ascribable to the methylene carbon of the cyclopropane ring at δ_c 30.9 (C-19), four oxygen-bearing methine carbons at δ_c 88.7 (C-3), 84.1 (C-24), 80.8 (C-15), and 73.7 (C-23), two oxygen-bearing quaternary carbons at δ_c 112.2 (C-16) and 68.8 (C-25), and a carbonyl group at δ_c 170.0. The ¹³C NMR spectroscopic data of **6** showed a close resemblance with those of 24-*epi*-cimigenol-3-*O*- β -D-xylopyranoside, except for the sugar unit (Li et al., 1993). The pentose moiety signals at δ_c 104.6 (*d*), 74.4 (*d*), 72.5 (*d*), 69.8 (*d*), and 67.3 (*t*) were identical with those of **1**, indicating that the sugar was 2'-*O*-acetyl-3-*O*- α -L-arabinose. This conclusion was confirmed by the presence of the HMBC correlation between the H-2' signal at δ_H 5.91 and the carbonyl group signal at δ_c 170.0. The configurations of C-23 and C-24 were considered to be *R* and *R*, respectively, by comparing the coupling constants of the C-23 and C-24 proton signals of **6** with those of known 9,19-cyclolanostane triterpene glycosides (Li et al., 1993). Ultimately, **6** was elucidated as 2'-*O*-acetyl-24-*epi*-cimigenol-3-*O*- α -L-arabinopyranoside.

Compound **7**, a white powder, gave a pseudo-molecular ion at m/z 685.3944 [M+Na]⁺ in the positive ion HR-ESIMS, corresponding to the molecular formula C₃₇H₅₈O₁₀, which is 42 Da less than those of 2',25-*O*-diacetylcimigenol-3-*O*- β -D-xylopyranoside (Zhou et al., 2004). When its spectroscopic data (Tables 1 and 2) were compared with those of 2',25-*O*-diacetylcimigenol-3-*O*- β -D-xylopyranoside, the resonances of an *O*-acetyl group were absent in **7**, showing instead a hydroxyl functionality at C-25. This deduction was confirmed by the upfield shift of C-25 by 11.8 ppm and correlations of δ_H 1.16 (H-27) and 1.27 (H-26) with δ_c 71.4 (C-25) in the HMBC spectrum. The relative configuration of **7** was proposed in a similar manner to that of **6**. Accordingly, compound **7** was characterized as 2'-*O*-acetylcimigenol-3-*O*- β -D-xylopyranoside.

Compound **8** was isolated as a white powder. The positive ion HR-ESIMS showed a pseudo-molecular ion at m/z 625.3707 [M+Na]⁺, leading to the molecular formula C₃₅H₅₄O₈, which is 58 Da less than 12-*O*-acetyl-25-anhydrocimigenol-3-*O*- α -L-arabinopyranoside (Chen et al., 2002). The DEPT spectrum of **8** differed from 12 β -*O*-acetyl-25-anhydrocimigenol-3-*O*- α -L-arabinopyranoside in that a methine at δ_c 77.3 (C-12) were transformed to a methylene at δ_c 34.1. This deduction was further supported by the HMBC correlation (Fig. 1) between H-11/C-12, and H-12/C-13, as well as by the upfield shift of C-11 and C-13 about 12.1 and 7.3 ppm in the ¹³C spectrum, respectively. Thus, compound **8** was characterized as 25-anhydrocimigenol-3-*O*- α -L-arabinopyranoside.

Compound **9**, isolated as a white powder, showed a pseudo-molecular ion at m/z 727 [M+Na]⁺ in the positive ion ESIMS. The ¹³C NMR and HRTOF-ESIMS (m/z : 727.4043 [M+Na]⁺) data determined its molecular formula as C₃₉H₆₀O₁₁. The ¹H and ¹³C NMR spectra of **9** resembled those of **12** except for the signals of a sugar moiety. In the ¹H NMR spectrum, the resonance for H-2' in **9** at δ_H 5.93 (*t*, *J* = 8.5 Hz) was shifted upfield to δ_H 4.29 (*t*, *J* = 8.6 Hz) in **12**, meanwhile the signal for H-4' was shifted downfield from δ_H 4.29 in **9** to δ_H 5.41 in **12**, which indicated that an acetoxy group is attached at C-2' in **9** instead of at C-4' in **12**. This conclusion was also supported by an analysis of the HMBC spectrum, which showed a correlation between H-2' at δ_H 5.93 and the acetoxy carbon at δ_c 170.0. The configurations of C-23 and C-24 were assigned as *R* and *S*, respectively, by comparing the coupling constants of H-23 and H-24 of **9** with those of known 9,19-cyclolanostane triterpene glycosides (Kusano et al., 1999). Therefore, compound **9** was identified as 2',23-*O*-diacetylshengmanol-3-*O*- α -L-arabinopyranoside.

Compound **10** was isolated as a white powder. In the high-resolution positive ESIMS, it showed a quasi-molecular ion at m/z 727.4017 [M+Na]⁺ for a molecular formula of C₃₉H₆₀O₁₁. In the ¹³C and DEPT spectrum (Table 2), **10** exhibited signals very similar

to those of 24-*O*-acetyl-25-anhydrohydroshengmanol-3-*O*- β -D-xylopyranoside (Nian et al., 2009) except for the sugar moiety. As for **9**, an acetyl group was determined to be at C-2' for **10**, which was further confirmed by the presence of the HMBC correlation between H-2' (δ_{H} 5.84) and the carbonyl carbon at δ_{C} 170.3. Compound **10** was treated with 4% K_2CO_3 , followed by 5% HOAc (Nian et al., 2009) to afford compound **8**. This conversion suggested the stereochemistry of the 23R and 24S configurations in **10**. Therefore, compound **10** was elucidated as 2',24-di-*O*-acetyl-25-anhydrohydroshengmanol-3-*O*- α -L-arabinopyranoside (**10**).

2.2. Cytotoxic activity

The cytotoxicities of these eighteen 9,19-cycloartane triterpenes (**1–18**) were evaluated against human HL-60, SMMC-7721, A549, SK-BR-3, and PANC-1 cell lines. Among them, **7**, **8**, and **15** exhibited broad-spectrum and moderate cytotoxicities with IC_{50} values ranging from 6.20 to 22.74 μM . Compound **5** exhibited moderate cytotoxicity against SMMC-7721 cell line and weak cytotoxicity against SK-BR-3 cell line, having IC_{50} values of 17.65 and 35.14 μM , respectively. Compounds **9** and **10** showed weak inhibition activities against HL-60 cell line, with IC_{50} values of 35.24 and 31.68 μM , respectively. Other compounds showed no cytotoxic activities up to a highest concentration of 40.00 μM , in any of the cell lines tested (Table 3).

2.3. Concluding remarks

Previously, we reported that a series of active compounds, isolated from the roots of *C. foetida* exhibited selective cytotoxicity against the human HepG2 cell line rather than against the MCF7, HT29 and MKN28 cell lines (Nian et al., 2010). With the purpose of finding cytotoxic 9,19-cycloartane triterpenoids with new targets and completely studying their active properties, we used five different human tumor cell lines to evaluate cytotoxicities of the isolated compounds in this study. As a result, compounds, such as **7**, **8**, and **15**, in contrast, exhibited moderate and broad-spectrum cytotoxicities against the testing cell lines.

Although a number of 9,19-cycloartane triterpene glycosides were isolated from the aerial parts of *C. foetida* (Pan et al., 2002, 2003, 2004, 2007, 2009; Tian et al., 2006), its chemical components are not completely known. In the present study, another 18 analogs, including seven aglycones, were isolated and identified for the first time. Based on the above results, we suggest that the main chemical constituents of the aerial parts of *C. foetida* are 9,19-cycloartane triterpenes and that the tissue may be a potential resource for promising antitumor agents.

Almost 50% of 9,19-cycloartane triterpenes from *Cimicifuga* species possess a cimigenol-skeleton (Li and Yu, 2006). Chemical constituents possessing the cimigenol-skeleton, such as 25-methoxycimigenol-3-*O*- α -L-arabinopyranoside (Watanabe et al., 2002), cimifugoside (Einbond et al., 2004), 25-*O*-anhydrocimigenol-3-*O*- β -D-xylopyranoside (Tian et al., 2006), cimicifoetisides A and B (Sun et al., 2007), 3',25-*O*-diacetylcimigenol-3-*O*- β -D-xylopyranoside (Nian et al., 2010), and **5**, **7**, **8**, and **15** in the present study, are the main cytotoxic constituents from *Cimicifuga* species. Based on the analysis of reported bioassay results, we may propose preliminary structure-activity relationships for active compounds with cimigenol-skeleton: (1) compounds with groups like acetyl or butenoyl attached to the sugar unit are more potent than those without such substituent; (2) the configurations of C-23 and C-24 should be R and S for activity; (3) hydrophobic groups, like acetoxy and methoxyl, instead of a hydroxyl group at C-25, or dehydration between C-25 and C-26 increase inhibition activities of these compounds.

3. Experimental

3.1. General experimental procedures

Optical rotations were measured in MeOH with a Horiba SEAP-300 polarimeter. ^1H and ^{13}C NMR spectra were recorded in pyridine- d_5 on Bruker AM-400 and DRX-500 spectrometers (Bruker, Zürich, Switzerland), using TMS as internal standard. ESIMS and HRTOF-ESIMS data were obtained using a VG Autospec-3000 spectrometer. Infrared spectra were recorded on a Shimadzu IR-450 instrument with KBr pellets. Thin-layer chromatography was performed on precoated TLC plates (Silica gel 60 F₂₅₄, Qingdao Marine Chemical, Inc.) and spots were visualized by heating after spraying with 10% H_2SO_4 . Silica gel (mesh 200–300, Qingdao Marine Chemical, Inc.), Lichroprep RP-18 (40–63 μm , Merck), Amberlite IR-35 (10 ml) column and Sephadex LH-20 (Pharmacia) were used for column chromatography (cc).

3.2. Plant material

Aerial parts of *Cimicifuga foetida* L. (10 kg) were collected from Shangrila County, Yunnan Province, China, in September 2007 and identified by Prof. Baogui Li, Xishuangbanna Tropical Botanical Garden, Chinese Academy of Science. A voucher specimen (KUN No. 200709004) has been deposited at the State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, PR China.

3.3. Extraction and isolation

The dried and milled aerial parts of *C. foetida* (10 kg) were extracted with MeOH (3 \times 20 L, 24 h each) at room temperature to give a residue (1243 g) after evaporating in vacuum at 50°. This residue was suspended in H_2O (2.5 L) and then extracted successively with petroleum ether (bp 40–60 °C), EtOAc and *n*-BuOH (3 \times 2.5 L each) to give petroleum ether-soluble (135 g), EtOAc-soluble (313 g), and *n*-BuOH-soluble (480 g) extracts. The EtOAc extract (313 g) was subjected to silica gel cc (2 kg, 15 \times 150 cm) eluted with CHCl_3 -MeOH [100:0 (2.5 L), 50:1 (4 L), 20:1 (8 L), 10:1 (10 L)] to afford fractions **1** (43 g), **2** (23 g), **3** (78 g) and **4** (91 g). Fraction **2** (23 g) was divided into four sub-fractions (**2.1–2.4**) after performing silica gel cc (200 g, 8 \times 60 cm), eluted with CHCl_3 -MeOH (gradient from 60:1 to 40:1, 4 L). Compounds **3** (13 mg), **4** (51 mg), **5** (29 mg), **11** (21 mg), **14** (9 mg), **16** (11 mg), and **18** (20 mg) were purified from fraction **2.2** (8.1 g) by conducting cc (5 \times 25 cm) on RP-18 (180 g), eluted with MeOH- H_2O (7:3, 4 L) and then Sephadex LH-20 (150 g, 2.5 \times 200 cm), eluted with MeOH (0.8 L each). Fraction **3** (78 g) was fractionated into three sub-fractions (**3.1–3.3**) by performing silica gel cc (400 g, 10 \times 80 cm), eluted with CHCl_3 -MeOH (gradient from 40:1 to 20:1, 8 L). Fraction **3.2** (16.6 g) was subjected to silica gel cc (200 g, 6 \times 60 cm) eluted with CHCl_3 - Me_2CO (4:1, 4 L), then RP-18 cc (180 g, 5 \times 25 cm), eluting with MeOH- H_2O (3:2, 3 L) to yield **1** (78 mg), **2** (59 mg), **6** (12 mg), **7** (11 mg), **8** (81 mg), **9** (25 mg) and **10** (26 mg), **12** (45 mg), **13** (21 mg). Fraction **3.3** (38 g) was applied to a silica gel (250 g) column (8 \times 60 cm) eluted with CHCl_3 - Me_2CO (gradient from 3:1 to 2:1, 8 L) to afford fractions **3.3.1–3.3.4**. Fraction **3.3.1** (9.5 g) was subjected to a RP-18 cc (180 g, 5 \times 25 cm), eluting with MeOH- H_2O (3:2, 4 L), then purified on Sephadex LH-20 (2.5 \times 200 cm, 150 g), eluting with MeOH (1 L) to afford **15** (320 mg). Compound **17** (280 mg) was crystallized in MeOH from Fraction **3.3.4** (7.8 g).

3.4. Acid hydrolysis

Compounds **1**, **9**, and **10** (15 mg of each), and **6** and **7** (10 mg of each) were individually dissolved in MeOH (15 mL), then 4% K₂CO₃ (15 mL) was added and each solution was stirred at room temperature overnight. Each solution was neutralized by 10% HOAc, and extracted with EtOAc (3 × 30 mL). Each EtOAc extract, after removal of solvent, was dissolved in MeOH (10 mL) and refluxed with 0.5 N HCl (3 mL) for 4 h (Nian et al., 2010). Compounds **2** and **8** (15 mg of each), by contrast, were directly individually dissolved in MeOH (10 mL) and refluxed with 0.5 N HCl (3 mL) for 4 h. Each reaction mixture was diluted with H₂O and extracted with CHCl₃ (3 × 20 mL). Each aqueous layer was then applied to an Amberlite IR-35 (10 mL) column and each resulting fraction was concentrated *in vacuo* to give a monosaccharide, which had an *Rf* (EtOAc–CHCl₃–MeOH–H₂O, 3:2:2:1) and specific rotation [α]_D²⁰ +84.06 (c 0.09, H₂O) corresponding to those of L-arabinose (Sigma–Aldrich); compound **7** was treated in same way as **1**, then identified the sugar with a *Rf* (EtOAc–CHCl₃–MeOH–H₂O, 3:2:2:1) and specific rotation [α]_D²⁰ +38.09 (c 0.07, H₂O) corresponding to those of D-xylose (Sigma–Aldrich).

3.5. Conversion of **10** to **8**

Compound **10** (10 mg) was dissolved in MeOH (10 mL), then 4% K₂CO₃ (10 mL) was added and the solution was stirred at room temperature overnight. The solution was neutralized with 5% HOAc, and then extracted with EtOAc (3 × 25 mL). The EtOAc part, after removal of the solvent, was dissolved in tetrahydrofuran (5 mL) and 5% HOAc (5 mL), then heated on a boiling water bath for 3 h. After evaporation of the solvent *in vacuo*, the products were subjected to silica gel cc, eluted with CHCl₃–MeCO 8:1 to afford **8** (7.6 mg).

3.6. 2',24-Di-O-acetylisodahurinol-3-O- α -L-arabinopyranoside (**1**)

White powder; [α]_D²⁰ 46.86 (MeOH, c 0.10); for ¹H and ¹³C (C₅D₅N) NMR spectroscopic data, see Tables 1 and 2; IR (KBr) ν_{max} 3410, 2938, 1741, 1632, 1383, 1243, 1085, 1041 cm⁻¹; ESIMS (positive ion mode) *m/z* 727 [M+Na]⁺; HRTOF-ESIMS (positive ion mode) *m/z* 727.4048 [M+Na]⁺ (calc. for C₃₉H₆₀O₁₁Na, 727.4033).

3.7. 24-O-Acetylisodahurinol-3-O- α -L-arabinopyranoside (**2**)

White powder; [α]_D²⁰ 42.03 (MeOH, c 0.10); for ¹H and ¹³C (C₅D₅N) NMR spectroscopic data, see Tables 1 and 2; IR (KBr) ν_{max} 3432, 2970, 2873, 1721, 1632, 1466, 1377, 1249, 1066, 981 cm⁻¹; ESIMS (positive ion mode) *m/z* 727 [M+Na]⁺; HRTOF-ESIMS (positive ion mode) *m/z* 685.3939 [M+Na]⁺ (calc. for C₃₇H₅₈O₁₀Na, 685.3927).

3.8. 12 β -Hydroxy-25-anhydrocimigenol (**3**)

White powder; [α]_D²⁰ 4.69 (MeOH, c 0.10); for ¹H and ¹³C (C₅D₅N) NMR spectroscopic data, see Tables 1 and 2; IR (KBr) ν_{max} 3423, 2938, 2870, 1726, 1648, 1459, 1382, 1148, 1066, 981 cm⁻¹; ESIMS (positive ion mode) *m/z* 509 [M+Na]⁺; HRTOF-ESIMS (positive ion mode) *m/z* 509.3256 [M+Na]⁺ (calc. for C₃₀H₄₆O₅Na, 509.3242).

3.9. Cimigenol-12-one (**4**)

White powder; [α]_D²⁰ 0.00 (MeOH, c 0.06); for ¹H and ¹³C (C₅D₅N) NMR spectroscopic data, see Tables 1 and 2; IR (KBr) ν_{max} 3431, 2933, 2870, 1709, 1451, 1383, 1168, 1024, 981 cm⁻¹; ESIMS (positive ion mode) *m/z* 525 [M+Na]⁺; HRTOF-ESIMS (positive ion mode) *m/z* 525.3198 [M+Na]⁺ (calc. for C₃₀H₄₆O₆Na, 525.3192).

3.10. 12 β -Hydroxy-15-deoxycimigenol (**5**)

White powder; [α]_D²⁰ 28.11 (MeOH, c 0.08); For ¹H and ¹³C (C₅D₅N) NMR spectroscopic data, see Tables 1 and 2; IR (KBr) ν_{max} 3462, 2927, 2857, 1462, 1034 cm⁻¹; ESIMS (negative ion mode) *m/z* 523 [M–Cl]⁻; HRTOF-ESIMS (negative ion mode) *m/z* 523.3198 [M+Cl]⁻ (calc. for C₃₀H₄₈OCl, 523.3190).

3.11. 2'-O-Acetyl-24-epi-cimigenol-3-O- α -L-arabinopyranoside (**6**)

White powder; [α]_D²⁰ 5.92 (MeOH, c 0.09); For ¹H and ¹³C (C₅D₅N) NMR spectroscopic data, see Tables 1 and 2; IR (KBr) ν_{max} 3462, 2959, 2870, 1733, 1457, 1253, 1167, 1072, 972 cm⁻¹; ESIMS (positive ion mode) *m/z* 685 [M+Na]⁺; HRTOF-ESIMS (positive ion mode) *m/z* 685.3915 [M+Na]⁺ (calc. for C₃₇H₅₈O₁₀Na, 685.3927).

3.12. 2'-O-Acetylcimigenol-3-O- β -D-xylopyranoside (**7**)

White powder; [α]_D²⁰ 16.48 (MeOH, c 0.09); For ¹H and ¹³C (C₅D₅N) NMR spectroscopic data, see Tables 1 and 2; IR (KBr) ν_{max} 3483, 2940, 2874, 1731, 1457, 1256, 1167, 1081 cm⁻¹; ESIMS (positive ion mode) *m/z* 685 [M+Na]⁺; HRTOF-ESIMS (positive ion mode) *m/z* 685.3944 [M+Na]⁺ (calc. for C₃₇H₅₈O₁₀Na, 685.3927).

3.13. 25-Anhydrocimigenol-3-O- α -L-arabinopyranoside (**8**)

White powder; [α]_D²⁰ 10.58 (MeOH, c 0.06); For ¹H and ¹³C (C₅D₅N) NMR spectroscopic data, see Tables 1 and 2; IR (KBr) ν_{max} 3463, 2960, 2869, 1631, 1430, 1256, 1073, 981 cm⁻¹; ESIMS (positive ion mode) *m/z* 625 [M+Na]⁺; HRTOF-ESIMS (positive ion mode) *m/z* 625.3707 [M+Na]⁺ (calc. for C₃₅H₅₄O₈Na, 625.3716).

3.14. 2',23-Di-O-acetylshengmanol-3-O- α -L-arabinopyranoside (**9**)

White powder; [α]_D²⁰ –10.17 (MeOH, c 0.08); For ¹H and ¹³C (C₅D₅N) NMR spectroscopic data, see Tables 1 and 2; IR (KBr) ν_{max} 3467, 2927, 2855, 1737, 1459, 1378, 1241, 1082, 992 cm⁻¹; ESIMS (positive ion mode) *m/z* 727 [M+Na]⁺; HRTOF-ESIMS (positive ion mode) *m/z* 727.4043 [M+Na]⁺ (calc. for C₃₉H₆₀O₁₁Na, 727.4033).

3.15. 2',24-Di-O-acetyl-25-anhydrohydroshengmanol-3-O- α -L-arabinopyranoside (**10**)

White powder; [α]_D²⁰ –11.26 (MeOH, c 0.07); for ¹H and ¹³C (C₅D₅N) NMR spectroscopic data, see Tables 1 and 2; IR (KBr) ν_{max} 3435, 2933, 2871, 2017, 1756, 1636, 1375, 1247, 1052, 973 cm⁻¹; ESIMS (positive ion mode) *m/z* 727 [M+Na]⁺; HRTOF-ESIMS (positive ion mode) *m/z* 727.4017 [M+Na]⁺ (calc. for C₃₉H₆₀O₁₁Na, 727.4033).

3.16. Cytotoxicity experiments

Cytotoxicity evaluations were performed using the MTT method for the human tumor HL-60, SMMC-7721, A549, SK-BR-3, and PANC-1 cells and cisplatin was used as a positive control (Zhou et al., 1993). Briefly, 2 × 10⁴/mL cells were added to each well (100 μ L/well), and incubated with various concentrations of drugs (100, 30, 10, 3, 1, 0.3 μ g/mL) in three replicates for 48 h at 37 °C in a humidified atmosphere of 5% CO₂. After 48 h, 20 μ L of methylthiazolyldiphenyl tetrazolium bromide (MTT) solution (5 mg/mL) were added to each well, which were incubated for another 4 h. Then 10% SDS–5% iB₄O₄–0.012 M HCl was added to each well (100 μ L/well). After 12 h at room temperature, the OD value of each well was recorded on a Model680 (Bio-Rad) reader at 595 nm.

Acknowledgments

This work was supported by the Foundation of the Key State Laboratory of Phytochemistry (No. P2008-ZZ05), the National Natural Science Foundation of China (No. 30772636) and National Science Foundation of Yunnan Province (No. 2005C0010Z).

References

- Compton, J.A., Culham, A., Gibbings, J.C., Jury, S.L., 1998a. Phylogeny of *Actaea* including *Cimicifuga* (Ranunculaceae) inferred from nrDNA ITS sequence variation. *Biochem. Syst. Ecol.* 26, 185–197.
- Compton, J.A., Culham, A., Jury, S.L., 1998b. Reclassification of *Actaea* to include *Cimicifuga* and *Souliea* (Ranunculaceae): phylogeny inferred from morphology, nrDNA ITS, and cpDNA trnL-F sequence variation. *Taxon* 47, 593–634.
- Chen, S.N., Fabricant, D.S., Lu, Z.Z., Fong, H.H.S., Farnsworth, N.R., 2002. Cimicifugosides I–P, new 9,19-cyclolanostane triterpene glycosides from *Cimicifuga racemosa*. *J. Nat. Prod.* 65, 1391–1397.
- Einbond, S.L., Shimizu, M., Xiao, D., Nuntanakorn, P., Lim, J.E., Suzui, M., Seter, C., Pertel, T., Kennelly, E.J., Kronenberg, F., Weinstein, I.B., 2004. Growth inhibitory activity of extracts and purified components of black cohosh on human breast cancer cells. *Breast Cancer Res. Treat.* 83, 221–231.
- Kusano, A., Shibano, M., Kusano, G., 1995. Study on the constituents of *Cimicifuga* species: VII. Four new glycosides from the aerial parts of *Cimicifuga simplex* Wormsk. *Chem. Pharm. Bull.* 43, 1167–1170.
- Kusano, A., Shibano, M., Kusano, G., 1999. Studies on the constituents of *Cimicifuga* species: XXVII. Malonyl cyclolanostanol glycosides from the underground parts of *Cimicifuga simplex* Wormsk. *Chem. Pharm. Bull.* 47, 1175–1179.
- Kusano, G., Murakami, Y., Sakurai, N., Takemoto, T., 1976. Studies on the constituents of *Cimicifuga* spp.: XI. Isolation and stereostructures of dahurinol, dehydroxydahurinol, isodahurinol and 25-O-methylisodahurinol. *Yakugaku Zasshi* 96, 82–85.
- Li, J.X., Kadota, S., Hattori, M., Yoshimachi, S., Shiro, M., Oogami, N., Mizuno, H., Namba, T., 1993. Constituents of *Cimicifuga* Rhizoma: I. Isolation and characterization of ten new cycloartenol triterpenes from *Cimicifuga heracleifolia* Komarov. *Chem. Pharm. Bull.* 41, 832–841.
- Li, J.X., Yu, Z.Y., 2006. *Cimicifuga* Rhizoma: from origins, bioactive constituents to clinical outcomes. *Curr. Med. Chem.* 13, 2927–2951.
- Liske, E., Wustenberg, P., 1998. Therapy of climacteric complaints with *Cimicifuga racemosa*: herbal medicine with clinically proven evidence. *Menopause* 5, 250–255.
- Lu, L., Chen, J.C., Song, H.J., Li, Y., Nian, Y., Qiu, M.H., 2010. Five new triterpene bisglycosides with acyclic side chains from the rhizomes of *Cimicifuga foetida* L. *Chem. Pharm. Bull.* 58, 729–733.
- Nian, Y., Chen, J.C., Lu, L., Zhang, X.M., Zhou, L., Qiu, M.H., 2009. Four new 9,19-cyclolanostane derivatives from the rhizomes of *Cimicifuga yunnanensis* Hsiao. *Helv. Chim. Acta* 92, 112–120.
- Nian, Y., Zhang, Y.L., Chen, J.C., Lu, L., Qing, C., Qiu, M.H., 2010. Cytotoxic chemical constituents from the roots of *Cimicifuga foetida*. *J. Nat. Prod.* 73, 93–98.
- Pan, R.L., Chen, D.H., Si, J.Y., Zhao, X.H., Sun, L.G., 2002. Studies on the triterpenoid constituents from the aerial part of *Cimicifuga foetida* L. *Acta Pharmacol. Sin.* 37, 117–120.
- Pan, R.L., Chen, D.H., Si, J.Y., Zhao, X.H., Sun, L.G., 2003. Studies on the chemical constituents of the aerial part of *Cimicifuga foetida* L. *Acta Pharmacol. Sin.* 38, 272–275.
- Pan, R.L., Chen, D.H., Si, J.Y., Zhao, X.H., Sun, L.G., 2004. Two new cyclolanostanol glycosides from the aerial parts of *Cimicifuga foetida*. *J. Asian Nat. Prod. Res.* 6, 63–67.
- Pan, R.L., Chen, D.H., Si, J.Y., Zhao, X.H., 2007. Cimifoetisides VI and VII two new cyclolanostanol triterpeneglycosides from the aerial parts of *Cimicifuga foetida*. *J. Asian Nat. Prod. Res.* 9, 97–102.
- Pan, R.L., Chen, D.H., Si, J.Y., Zhao, X.H., Li, Z., Cao, L., 2009. Immunosuppressive effects of new cyclolanostane triterpene diglycosides from the aerial part of *Cimicifuga foetida*. *Arch. Pharmacol. Res.* 32, 185–190.
- Pharmacopoeia Commission of the People's Republic of China, 2005. The Pharmacopoeia of Chinese People's Republic. The Chemical Industry Publishing House, Beijing, p. 50.
- Shao, Y., Harris, A., Wang, M.F., Zhang, H.J., Cordell, G.A., Bowman, M., Lemmo, E., 2000. Triterpene glycosides from *Cimicifuga racemosa*. *J. Nat. Prod.* 63, 905–910.
- Sun, L.R., Qing, C., Zhang, Y.L., Ji, S.Y., Li, Z.R., Pei, S.J., Qiu, M.H., Gross, M.L., Qiu, S.X., 2007. Cimifoetisides A and B, two cytotoxic cycloartane triterpenoid glycosides from the rhizomes of *Cimicifuga foetida*, inhibit proliferation of cancer cells. *Beilstein J. Org. Chem.* 3, 1–6.
- Tian, Z., Pan, R.L., Si, J.Y., Xiao, P.G., 2006. Cytotoxicity of cycloartane triterpenoids from aerial part of *Cimicifuga foetida*. *Fitoterapia* 77, 39–42.
- Tian, Z., Pan, R.L., Qi, C.G., Si, J.Y., Xiao, P.G., Wu, Z., 2007. *Cimicifuga foetida* extract inhibits proliferation of hepatocellular cells via induction of cell cycle arrest and apoptosis. *J. Ethnopharmacol.* 114, 227–233.
- Watanbe, K., Mimaki, Y., Sakagami, H., Sashida, Y., 2002. Cycloartane glycosides from the rhizomes of *Cimicifuga racemosa* and their cytotoxic activities. *Chem. Pharm. Bull.* 50, 121–125.
- Ye, W., Zhang, J., Che, C.T., Ye, T., Zhao, S., 1999. New cycloartane glycosides from *Cimicifuga dahurica*. *Planta Med.* 65, 770–772.
- Yoshimitsu, H., Nishida, M., Sakaguchi, M., Noharac, M., 2006. Two new 15-deoxycimigenol-type and three new 24-*epi*-cimigenol-type glycosides from *Cimicifuga* rhizome. *Chem. Pharm. Bull.* 54, 1322–1325.
- Zhou, L., Yang, J.S., Zou, J.H., Tu, G.Z., 2004. Three new cycloartane triterpene glycoside from *Souliea vaginata*. *Chem. Pharm. Bull.* 52, 622–624.
- Zhou, J.J., Yue, X.F., Han, J.X., Yang, W.Y., 1993. Improved MTT assay for activity of antitumor agents. *Chin. J. Pharm.* 24, 455–457.